Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00660270 · ClinicalTrials.gov registry record · Phase 2

Chemotherapy and Radiation Following Pancreatic Surgery

A Phase 2 study, sponsored by Washington University School of Medicine.

Completed
Registry status
Phase 2
Development phase
53
Enrollment target

NCT00660270 is a Phase 2 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 53 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00660270, a Phase 2 study, has completed, sponsored by Washington University School of Medicine.

COMPLETED
Registry status
Phase 2
Development phase
53 participants
Enrollment target

Study Summary

To describe the overall survival and disease-free survival in pancreatic cancer patients treated with adjuvant chemoradiation with cisplatin, continuous infusion 5FU and interferon alpha followed by gemcitabine. To describe the toxicities associated with adjuvant chemoradiation with cisplatin. 5FU and interferon alfa followed by gemcitabine in patients with pancreatic cancers.

Interventions

  • DRUG Cisplatin
  • RADIATION Radiation therapy
  • DRUG 5-FU
  • PROCEDURE Pancreatic Surgery
  • DRUG Alpha-interferon

Trial Details

FieldValue
Enrollment Target 53 participants
Start Date 2002-05
Est. Completion 2009-02
Phase Phase 2

What the Registry Record Tells You About NCT00660270

The ClinicalTrials.gov registry entry for NCT00660270 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 5 interventions - of which Cisplatin is the first listed.

NCT00660270 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00660270 about?

NCT00660270 is a clinical study titled "Chemotherapy and Radiation Following Pancreatic Surgery". To describe the overall survival and disease-free survival in pancreatic cancer patients treated with adjuvant chemoradiation with cisplatin, continuous infusion 5FU and interferon alpha followed by gemcitabine. To describe the toxicities associated with adjuvant chemoradiation with cisplatin. 5FU ...

What is the current status of trial NCT00660270?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2002-05. Estimated completion is 2009-02.

What interventions are being tested in trial NCT00660270?

The interventions under investigation include: Cisplatin (DRUG), Radiation therapy (RADIATION), 5-FU (DRUG), Pancreatic Surgery (PROCEDURE), Alpha-interferon (DRUG).

Who is sponsoring clinical trial NCT00660270?

This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.